Celldex Therapeutics (NASDAQ:CLDX) Trading Up 8.1% – What’s Next?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was up 8.1% during mid-day trading on Wednesday . The company traded as high as $28.65 and last traded at $28.35. Approximately 116,804 shares were traded during trading, a decline of 89% from the average daily volume of 1,066,330 shares. The stock had previously closed at $26.22.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CLDX shares. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target on the stock. Citigroup started coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, November 20th. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Finally, Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Trading Up 1.9 %

The stock has a market cap of $1.76 billion, a P/E ratio of -10.14 and a beta of 1.57. The stock has a 50 day simple moving average of $27.93 and a 200 day simple moving average of $34.10.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci purchased 11,500 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $76,000. KBC Group NV boosted its holdings in Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares during the last quarter. Los Angeles Capital Management LLC increased its position in shares of Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 638 shares during the period. Quest Partners LLC raised its stake in Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 6,879 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 1,504 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.